Company
Every investor coverage indicates participated in a round Johnson & Johnson Innovation raised.
Companies Johnson & Johnson Innovation acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Johnson & Johnson Innovation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.
Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.
Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.
Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.
Melbourne's ENA Respiratory has won a further US$3.18 million US Defense Department contract to widen its INNA-051 Phase Ib trial to younger adults, extending the US$8.18 million the agency had already committed.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·enarespiratory.com